Press Releases - 2004

	Jerusalem, Israel, December 21, 2004 Teva Board Of Directors Increases Repurchase Program To Up To $600 Million Of Teva Securities
	Jerusalem, Israel, December 21, 2004 Teva Announces Tentative Approval Of Rosiglitazone Maleate Tablets
	Jerusalem, Israel, December 16, 2004 Teva Launches Quinapril Hcl Tablets; Pursuant To Agreement With Ranbaxy
	Jerusalem, Israel, December 15, 2004 Teva Announces Approval And Launch Of Gabapentin Tablets
	Jerusalem, Israel, December 14, 2004 Teva Announces Tentative Approval Of Metformin Hcl Extended Release Tablets, 750 Mg
	Jerusalem, Israel, December 10, 2004 Teva Announces Tentative Approval Of Oxycodone Hydrochloride Er Tablets, 10 Mg, 20 Mg, And 40 Mg
	Jerusalem, Israel, December 1, 2004 Teva Closes Acquisition Of Pfizer's Italian Generic Pharmaceutical Operation - Dorom
	Jerusalem, Israel, November 30, 2004 Teva Announces Promotions and Additions to its Management Team
	Jerusalem, Israel, November 24, 2004 Teva Announces Approval Of Cilostazol Tablets
	Jerusalem, Israel, November 21, 2004 Teva Announces Tentative Approval Of Fosphenytoin Sodium Injection
	Jerusalem, Israel, Copenhagen, Denmark, November 18, 2004 Teva and Lundbeck announce that Azilect® (rasagiline) for Parkinson's disease is recommended for approval in the EU
	Jerusalem, Israel, October 27, 2004 Teva Announces Approval Of Medroxyprogesterone Acetate Pre-Filled Syringe
	Jerusalem, Israel, October 27, 2004 Teva Announces Tentative Approval Of Finasteride Tablets Usp, 5 Mg
	Jerusalem, Israel, October 21, 2004 Teva Announces Third Quarter Global In-Market Sales Of Copaxone Increased 34% To $242 Million
	Jerusalem, Israel, October 18, 2004 Teva Announces Approval Of Cefuroxime Axetil Tablets
	Jerusalem, Israel, October 15, 2004 Teva To Report Third Quarter 2004 Financial Results On November 4, 2004
	Jerusalem, Israel, October 13, 2004 Teva Announces Approval Of Flumazenil Injection
	Jerusalem, Israel, October 8, 2004 Teva Announces Final Approval And Launch Of Gabapentin Capsules
	Jerusalem, Israel, October 4, 2004 Teva Announces Approval Of Ribavirin Capsules
	Jerusalem, Israel, October 1, 2004 Teva And Biovail Announce Resolution Of Arbitration Proceedings; Expansion Of Relationship
	Jerusalem, Israel, October 1, 2004 Teva Announces Approval Of Mesalamine Rectal Suspension Usp
	Jerusalem, Israel, September 22, 2004 Teva Announces Tentative Approval Of Cetirizine Hcl Tablets
	Jerusalem, Israel, September 13, 2004 Teva Enters Into Agreement With Schwarz Pharma to Suspend Sales of Moexipril Pending Outcome of Litigation
	Jerusalem, Israel, September 3, 2004 Teva Board Of Directors Authorizes The Repurchase Of Up To $300 Million Of Teva Securities
	Jerusalem, Israel and Lund, Sweden, August 24, 2004 FTC CLEARS TEVA/ACTIVE BIOTECH AGREEMENT
	Jerusalem, Israel, August 20, 2004 Teva Announces Conversion Of 0.75% Convertible Debentures Due 2021
	Jerusalem, Israel, August 17, 2004 Teva Announces Agreement To Acquire Pfizer's Italian Generic Pharmaceutical Operation
	Jerusalem, Israel, August 12, 2004 Teva Comments On Recent Share Price Decline
	Jerusalem, Israel, August 5, 2004 Teva and Savient Receive Favorable Court Ruling on Human Growth Hormone Patent Suits
	Jerusalem, Israel, August 3, 2004 Teva Reports Record Sales And Net Income In Q2
	Jerusalem, Israel, July 30, 2004 Teva Calls 0.75% Convertible Debentures Due 2021 For Redemption
	Jerusalem, Israel, July 29, 2004 Teva Announces Approval Of Fluconazole Tablets And Injection
	Jerusalem, Israel, July 29, 2004 Teva Announces Approval Of Medroxyprogesterone Acetate Injectable Suspension
	Jerusalem, Israel, July 21, 2004 Teva Announces Approval Of Terbutaline Sulfate Injection
	Jerusalem, Israel, July 20, 2004 Teva To Report Second Quarter 2004 Financial Results On August 3, 2004
	Jerusalem, Israel, July 5, 2004 Teva Receives Approvable Letter For Agilect® (Rasagiline)
	Jerusalem, Israel, June 30, 2004 Teva Comments On Quinapril Court Ruling
	Jerusalem, Israel, June 24, 2004 Teva Commences Shipments Of Carboplatin
	Jerusalem, Israel, June 18, 2004 Teva Announces Approval Of Metformin Hcl Er Tablets
	Jerusalem, Israel, June 17, 2004 Teva And Aventis Announce That Copaxone ® Pre-Filled Syringe Is Now Available Also In Europe
	Jerusalem, Israel, June 16, 2004 Teva Announces Approval Of Adenosine Injection
	Jerusalem, Israel,, June 14, 2004 Teva Announces a Two for One Stock Split
	Jerusalem, Israel, and Lund, Sweden, June 14, 2004 Teva And Active Biotech Announce Agreement For Laquinimod Potential Oral Therapy For Multiple Sclerosis
	Jerusalem, Israel, June 9, 2004 Teva Announces Approval Of Ciprofloxacin Tablets
	Jerusalem, Israel, June 9, 2004 Teva Announces Tentative Approval Of Carvedilol Tablets
	Jerusalem, Israel, May 30, 2004 Teva Commences Commercial Launch of Generic Zyban®
	Jerusalem, Israel, May 25, 2004 Teva Announces Approval Of Amoxicillin And Clavulanate Potassium For Oral Suspension, 200 mg and 400 mg
	Jerusalem, May 19, 2004 Teva Comments On The Court Of Appeals Decision Regarding Generic Version Of Vicoprofen®
	Jerusalem, Israel, May 4, 2004 Teva Q1 2004 Sales Exceed $ 1 Billion For The First Time
	Jerusalem, Israel, April 29, 2004 Teva Announces Approval Of Fludarabine Phosphate Injection
	Jerusalem, Israel, April 28, 2004 Teva And Alpharma Enter Into Agreement Relating To Gabapentin
	Jerusalem, Israel, April 27, 2004 Teva Announces Settlement Of Carboplatin Litigation With Bristol-Myers Squibb; Will Market And Sell Product In The U.S.
	Jerusalem, Israel, April 26, 2004 Teva Announces Tentative Approval Of Levofloxacin Tablets, 250 Mg, 500 Mg, And 750 Mg
	Jerusalem, Israel, April 26, 2004 Teva To Report First Quarter 2004 Financial Results On May 4, 2004
	Jerusalem, Israel, April 25, 2004 Teva Announces Tentative Approval Of Flumazenil Injection
	Jerusalem, Israel, March 30, 2004 Teva Initiates Commercialization of Oxycodone 80 Mg
	Jerusalem, Israel, March 22, 2004 Teva Commences Commercial Launch Of Bupropion 150 Mg
	Jerusalem, Israel, March 12, 2004 Teva Announces Approval Of Amoxicillin/Clavulanate Potassium For Oral Suspension
	Jerusalem, Israel, March 8, 2004 Teva Announces Tentative Approval Of Fenofibrate Tablets, 54 Mg, 160 Mg
	Jerusalem, Israel, March 2, 2004 Teva Comments On Biovail Arbitration Claim
	Jerusalem, Israel, February 17, 2004 Teva Reports Record Sales And Net Income For Q4 2003
	Jerusalem, Israel, February 11, 2004 Teva Announces Final Approval Of Benazepril Hcl Tablets, 5 Mg, 10 Mg, 20 Mg, And 40 Mg
	Jerusalem, Israel, February 5, 2004 Teva Announces Exercise Of Over-Allotment Option For Convertible Debentures
	Jerusalem, Israel, February 1, 2004 Teva To Report Fourth Quarter 2003 Financial Results On February 17, 2004
	Jerusalem, Israel, January 31, 2004 Teva Comments On The Court Of Appeals Decision Regarding Moexipril
	Jerusalem, Israel, January 22, 2004 Teva Announces Pricing Of $1 Billion Convertible Debenture Offering
	Jerusalem, Israel, January 22, 2004 Teva Completes Acquisition of Sicor
	Jerusalem, Israel, January 21, 2004 Teva Announces an Offering of Approximately $ 1 Billion of Convertible Debentures
	Jerusalem, Israel and Irvine, California, January 18, 2004 FTC Grants Early Termination of HSR Waiting Period on Teva Sicor Merger
	Jerusalem, Israel, January 6, 2004 Teva Announces Approval Of Metolazone Tablets, 2.5 Mg And 10 Mg